Bevacizumab HY-P9906 from MedChemExpress

Product Specs
ItemBevacizumab
CompanyMedChemExpress
Price $160.00Supplier Page View Company Product Page
Catalog NumberHY-P9906
ApplicationsBioactivity, Structure and function analysis, ELISA, SDS-PAGE, Western blotting
Purity≥99.0%
Research AreaCancer
TypeChemical
Quantity1 mg
Molecule NameBevacizumab
Molecular Weight149 kDa(Average)

Add to Compare List

MedChemExpress

1 Deer Park Drive, Suite F

MONMOUTH JUNCTION, NJ 08852

United States

Phone: US Tel: 609-228-6898
US Fax: 609-228-5909
EU Tel: +4686500910

Email: sales@medchemexpress.com
eu.sales@MedChemExpress.com

Company Profile

Website: medchemexpress.com

(1) Low-intensity pulsed ultrasound combined with microbubbles enhances amphotericin B delivery across the blood-brain barrier for improved therapy of cryptococcal meningitisDrug DelivDecember 31, 2026Junyu Liu, Zhengtu Li, Dongcheng Li, Jia Liu, Yutian Su, Yifei Leng, Yongming Li, Li Xu, Lan Sun, Xiaohong Su, et al.(Wuhan, China). Bevacizumab was purchased from MedChemExpress (Monmouth Junction, NJ, USA; Cat. No. HY-P9906). IBA1 antibody (anti-mouse, CY7217) was purchased from ABWAYS, and GFAP antibody (anti-mouse, 16825-1-AP)

(2) Self-assembly of tumor-related vascularized colorectal tumoroid-on-a-chip for precision medicine drug testingCell Reports MedicineJuly 21, 2026Zhe Dai, Gongbo Fu, Yuanyang Du, Yiyang Xie, Jialong Zhu, Xiaoyue Tao, Qinghuizi Luo, Xiaoyuan Chu, Zengjie LeiPuro),GenePharma,Cat#D03007 Regorafenib,MCE,Cat#HY-10331 Fruquintinib,MCE,Cat#HY-19912 Sorafenib,MCE,Cat#HY-10201 Sunitinib,MCE,Cat#HY-10255A Apatinib,MCE,Cat#HY-13342S Bevacizumab,MCE,Cat#HY-P9906 5-Fu,MCE,Cat#HY-90006 Folinic acid calcium,MCE,Cat#HY-13664 Oxaliplatin,MCE,Cat#HY-17371 ,, Critical

(3) RBM15/IGF2BP2–PTPRH m6A regulatory axis in non-small cell lung cancerCell Oncol (Dordr)May 11, 2026Keyue Qiu, Xiaoxiao Zheng, Hongxiang Li, Jiaheng Zhang, Zijun Xie, Hang Chen, Zeyang Hu, Yiyi Sun, Zhe Chen, Jingtao Tong, et al.VEGF-neutralization experiments, conditioned medium was pre-incubated with 1 µg/mL bevacizumab (Cat. No. HY-P9906; MedChemExpress) or an equivalent concentration of human IgG1 kappa isotype control (Cat. No. HY-P99001;

(4) Tumor-like proliferation of CCM3 knockout endothelial cells: insights from semaxinib treatment and transcriptome profiling of co-culturesActa Neuropathol CommunApril 20, 2026Valeriia V. Saenko, Janne L. Feldmann, Dariush Skowronek, Debora Singer, Ole J. Schamuhn, Doreen Biedenweg, Sander Bekeschus, Ute Felbor, Matthias Rath, Robin A. PilzUSA), (Z)-semaxinib (#T2496, TargetMol), VEGFA (#100-20-50, Peprotech, Hamburg, Germany), bevacizumab (#HY-P9906, MedChemExpress), CH-223191 (#182705, Sigma-Aldrich), FICZ (#SML1489, Sigma-Aldrich), SC79 (#123871,

(5) Paris saponin VII suppresses osteosarcoma progression by targeting VEGFR2 and PD-L1 to enhance anti-angiogenic and immunotherapeutic efficacyCancer Cell InternationalApril 6, 2026Qilong Lai, Guanyi Gong, Peijie You, Zheng Yan, Yicheng Zhu, Suliang Xu, Junlong He, Xiaochun Li, Jintao Liu, Liu YangCat# HY-N3584; HPLC purity ≥ 98%; water-insoluble). Bevacizumab was obtained from MedChemExpress (Cat# HY-P9906; HPLC purity ≥ 98%; water-insoluble). Anti-PD-1 monoclonal antibody and the corresponding isotype control

(6) PER2 knockdown drives immunotherapy resistance in gastric cancer via metabolic reprogramming of myeloid-derived suppressor cellsCancer & MetabolismApril 2, 2026Shenggang Zhan, Shixi Lu, Feng Xiong, Haitao Li, Wenbiao Cheninterleukin-6 (IL-6, 501103, BioLegend, USA) and Bevacizumab (anti-vascular endothelial growth factor (VEGF), HY-P9906, MedChemExpress, USA) were added to the co-culture system for blocking experiments. The final concentration

(7) Preferential crosstalk between perifollicular capillary vessels and dermal papilla cells during hair cycling homeostasisScientific ReportsApril 1, 2026Ying Zeng, Akinari Abe, Satsuki Takashima, Miyu Kono, Reina Kagiyama, Mariko Komabayashi-Suzuki, Mariko Moriyama, Hiroyuki Moriyama, Tadashi Okamoto, Hideya Ando, et al.consists of all the ingredients solution except for MD. The VEGF-A monoclonal antibody bevacizumab (Bev) (#HY-P9906, Avastin), anti-CCL2-neutralizing antibody (A2132), and recombinant human CCL2 (#AF-300–04) were purchased

(8) Propofol attenuates angiogenesis by activating endoplasmic reticulum stress to suppress TFAP2C-driven VEGFA transcriptionApoptosisJanuary 12, 2026Fan Yang, Yi Liu, Hui Li, Xue Shang, Qing Hua, Yun Zhu, Beibei Tao, Zhirong SunRapamycin (HY-10219, MedChemExpress, China), MHY1485 (HY-B0795, MedChemExpress, China) and Bevacizumab (HY-P9906, MedChemExpress, China) were prepared as base solution according to the instructions. Propofol was administered

(9) Hypoxia-driven remodeling of SELENOP+ macrophages shapes T cell dynamics and promotes ovarian cancer metastasisNature CommunicationsJanuary 12, 2026Qing Liu, Chenzhao Feng, Tianhao Wu, Siyang Zhang, Xinyi Wang, Qian Zhao, Xueying Song, Shuangyan Liu, Linru Quan, Yuli Zhang, et al.conducted by supplementing the cultures with 50 µg/mL anti-human/mouse VEGFA neutralizing antibody (Cat#HY-P9906, MedChemExpress; Cat# 512810, BioLegend). Following incubation, cells were harvested and total protein

(10) Single‐Nucleus Multi‐Omics Reveals Hypoxia‐Driven Angiogenic Programs and Their Epigenetic Control in Sinonasal Squamous Cell CarcinomaAdvanced ScienceJanuary 7, 2026Chaelin You, Jaewoo Park, Jung Yeon Jang, Junho Noh, Jaehyun Lee, Geunho Kwon, Myeong Sang Yu, Yoo‐Sam Chung, Seung‐Jun Lee, Keunsoo Kang, et al.VEGF neutralization, the CM was pre‐incubated with 10 µg/mL Bevacizumab (MedChemExpress, Catalog no. HY‐P9906) for 1 h prior to treatment. Immediately following treatment, cells were harvested using TrypLE Express

(11) CD146 + pericyte-like lung cancer brain metastatic stem cells promote tumor angiogenesis through dual regulatory effects on the VEGF/VEGFR axisTheranosticsJanuary 1, 2026Wenwen Liu, Wenzhe Duan, Shengkai Xia, Ye Liu, Huiying Chu, Kun Liang, Shaobo Fang, Manqing Lin, Song Wei, Xin You, et al.(HY-P78813), Bemcentinib (R428/BGB324, HY-15150 for in vitro assays), Stattic (HY-13818) and Bevacizumab (HY-P9906) was bought from MedChemExpress. Ki8751 (S1363) was bought from Selleck. Matrigel (354263) was brought

(12) Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinomaNature communicationsNovember 18, 2025Tang C, He C, Wang D, Guo J, Yin X, Ye H, Wu L, Zhang Y, Zeng S, Zeng X, et al.Sorafenib (#HY-10201), Lenvatinib (#HY-10981), viFSP1 (#HY-163002), Atezolizumab (#HY-P9904), Bevacizumab (#HY-P9906), Liproxstatin-1 (#HY-12726), Z-VAD-FMK (#HY-16658B), Necrostatin-1 (#HY-15760), D-Luciferin potassium

(13) UHRF1-mediated HIF-1α stabilization promotes ovarian cancer through metabolic reprogramming and angiogenesisCell Death DisOctober 24, 2025Yuanna Jiang, Fang Peng, Yibo Chen, Aoyu Fu, Ruichen Yang, Ziyue Yang, Qian Wang, Lanqin Caomeasured, 5000 cells were inoculated into a 96-well plate, and eight concentrations of bevacizumab (HY-P9906, MedChemExpress) were added the next day at 0.05, 0.1, 0.5, 1, 2, 3, 4, 5, and 6 mg/mL. After 48 h,

(14) A Complementarity‐Based Approach to De Novo Binder DesignAdvanced ScienceSeptember 1, 2025Kateryna Maksymenko, Valeriia Hatskovska, Murray Coles, Narges Aghaallaei, Natalia Pashkovskaia, Natalia Borbarán‐Bravo, Matteo Pilz, Philip Bucher, Mareike Volz, Joana Pereira, et al.standard amine coupling chemistry. 500 nm VEGF (BioLegend, 583706), 100 nm bevacizumab (MedChemExpress, HY‐P9906), or a mixture of 500 nm VEGF and 100 nm bevazicumab preincubated for 30 min at room temperature were

(15) Thermosensitive hydrogel composite with si-Cx43 nanoparticles and anti-VEGF agent for synergistic treatment of diabetic retinopathyMaterials Today BioMay 29, 2025Lihui Wen, Mengxin Gan, Siying Xiong, Li Dai, Wen Chen, Wen Shipurged with nitrogen, followed by lyophilization. si-Cx43 LPPs (1 mg/mL) and Avastin (VEGFA antibody, HY-P9906, MedChemExpress, Monmouth Junction, NJ, USA) (25 mg/mL) were incorporated into the 3 % thermosensitive

(16) Wearable electrodriven switch actively delivers macromolecular drugs to fundus in non-invasive and controllable mannersNature communicationsJanuary 2, 2025Qin X, Shi H, Li H, Chu B, Zhang J, Wen Z, Sun X, Wang H, He Y.S1061S), anti-PDL1 (Bio X Cell Biotech Co., Ltd., catalogue no. BE0101), and anti-VEGF (MCE, catalogue no. HY-P9906) antibodies were used. The rat lgG ELISA kit (Elabscience, catalogue no. E-EL-R0518), anti-occludin

(17) Atractylenolide I inhibits angiogenesis and reverses sunitinib resistance in clear cell renal cell carcinoma through ATP6V0D2-mediated autophagic degradation of EPAS1/HIF2αAutophagyNovember 4, 2024Qinyu Li, Kai Zeng, Qian Chen, Chenglin Han, Xi Wang, Beining Li, Jianping Miao, Bolong Zheng, Jihong Liu, Xianglin Yuan, et al.samples for scientific research. Chemical reagents Cells were treated with bevacizumab (MedChemExpress, HYP9906) at 50 ng/ml or ATL-I (MedChemExpress, HY-N0201) at specified concentrations. Cycloheximide (MedChemExpress,

(18) Magnetically Integrated Tumor–Vascular Interface System to Mimic Pro-angiogenic Endothelial Dysregulations for On-Chip Drug TestingACS Applied Materials & InterfacesSeptember 11, 2024Vikram Surendran, Simrit Safarulla, Christian Griffith, Reem Ali, Ankit Madan, William Polacheck, Arvind Chandrasekarantargeted the Notch signaling pathway using nirogacestat, a selective γ-secretase inhibitor. Bevacizumab (HY-P9906, MedChemExpress, NJ, USA) was prepared to a concentration of 0.01 mg/mL in endothelial growth media.

(19) Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab TherapyCancer Cell InternationalAugust 23, 2024Jiasheng Zhou, Xue Liu, Qi Dong, Jiao Li, Weidong Niu, Tingjiao Liumixed with PBS (50 µL), rVEGF189 (100 ng/mL) or EVs (100 µg) with or without bevacizumab (0.25 mg/mL) (HY-P9906, MCE) or surfen (200 µM) (HY-122704 A, MCE), the mixture was injected subcutaneously into ventral region

(20) Pattern recognition of microcirculation with super-resolution ultrasound imaging provides markers for early tumor response to anti-angiogenic therapyTheranosticsJanuary 20, 2024Jingyi Yin, Feihong Dong, Jian An, Tianyu Guo, Heping Cheng, Jiabin Zhang, Jue Zhanganimal studies 31-33. The clinically used antiangiogenic agent bevacizumab (MedChemExpress, NJ, USA, #HY-P9906) was diluted in phosphate-buffered saline (PBS, pH 7.4, Hyclone, USA), and was administered every other

Be the First to Write a Review!

Bevacizumab from MedChemExpress

Description

MedChemExpress

Citations (34)

Reviews

Bevacizumab from MedChemExpress

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map